Anna Lamb
Family Medicine · Odon, INNPI 1841241361
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,477 of the $6,713 with a category attached, or 81.6%. It is spread thinly across 41 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,546 and has fallen 92.8% since, to $257 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$852
- AbbVie$778
- GSK$406
- Lilly USA, LLC$371
- Johnson & Johnson$310
- plus $3K from 35 others
What the payments were for
- Travel & lodging$1,19418%
- Food & beverage$5,47782%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ClosureFast$1,047
- REXULTI$125
- Mavyret$120
- BOTOX$112
How this compares
$6,713 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 19 | $22,322 |
| OzempicSemaglutide | 20 | $20,629 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $13,209 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 33 | $4,113 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 17 | $1,549 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $991 |
| Buprenorphine Hcl | 15 | $918 |
| Gabapentin | 59 | $855 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 56 | $828 |
| Levothyroxine Sodium | 52 | $674 |
| Valsartan | 33 | $655 |
| Pentips Pen NeedlePen Needle, Diabetic | 14 | $622 |
| Metoprolol Succinate | 30 | $600 |
| Triamcinolone Acetonide | 16 | $433 |
| Escitalopram Oxalate | 32 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $186 | $22,32219 claims |
| Novo NordiskOzempic | $852 | $20,62920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Odon
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.